CU20220047A7 - 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio monohidrato y su preparación - Google Patents

2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio monohidrato y su preparación

Info

Publication number
CU20220047A7
CU20220047A7 CU2022000047A CU20220047A CU20220047A7 CU 20220047 A7 CU20220047 A7 CU 20220047A7 CU 2022000047 A CU2022000047 A CU 2022000047A CU 20220047 A CU20220047 A CU 20220047A CU 20220047 A7 CU20220047 A7 CU 20220047A7
Authority
CU
Cuba
Prior art keywords
quinazolin
piperazin
trifluoromethyl
fluoro
methoxy
Prior art date
Application number
CU2022000047A
Other languages
English (en)
Inventor
Helmut Buschmann
Bertran Jordi Carles Ceron
Thomas Goldner
Original Assignee
Aic246 Ag & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aic246 Ag & Co Kg filed Critical Aic246 Ag & Co Kg
Publication of CU20220047A7 publication Critical patent/CU20220047A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>La presente invención se refiere a Ia nueva 3,4-dihidroquinazolina, 2-[(4<em>S</em>)-8-fluoro-2-[4-(3-metoxifeniI)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)feniI]-4<em>H</em>­-quinazolin-4-il] acetato de sodio monohidrato de fórmula I</p> <p>Fórmula I</p> <p>métodos para su preparación, así como composiciones farmacéuticas que contienen dicha 3,4-dihidroquinazolina. Dicho compuesto es particularmente útil para el tratamiento y prevención de enfermedades asociadas con citomegalovirus (CMV), particularmente citomegalovirus humano (HCMV).<br /> </p>
CU2022000047A 2020-02-27 2021-03-01 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio monohidrato y su preparación CU20220047A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20159709 2020-02-27
PCT/EP2021/055065 WO2021170879A1 (en) 2020-02-27 2021-03-01 Sodium 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate monohydrate, its preparation and use

Publications (1)

Publication Number Publication Date
CU20220047A7 true CU20220047A7 (es) 2023-04-10

Family

ID=69742712

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2022000047A CU20220047A7 (es) 2020-02-27 2021-03-01 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio monohidrato y su preparación

Country Status (19)

Country Link
US (1) US20230219900A1 (es)
EP (1) EP4110469A1 (es)
JP (1) JP2023519809A (es)
KR (1) KR20220147655A (es)
CN (1) CN115427111A (es)
AR (1) AR121440A1 (es)
AU (1) AU2021225364A1 (es)
BR (1) BR112022016906A2 (es)
CA (1) CA3169473A1 (es)
CL (1) CL2022002290A1 (es)
CO (1) CO2022012017A2 (es)
CU (1) CU20220047A7 (es)
EC (1) ECSP22066670A (es)
IL (1) IL295633A (es)
MX (1) MX2022010440A (es)
PE (1) PE20230347A1 (es)
TW (1) TW202140454A (es)
UY (1) UY39098A (es)
WO (1) WO2021170879A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024037485A1 (zh) * 2022-08-15 2024-02-22 上海迪赛诺化学制药有限公司 一种来特莫韦无定形的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats

Also Published As

Publication number Publication date
KR20220147655A (ko) 2022-11-03
CA3169473A1 (en) 2021-09-02
BR112022016906A2 (pt) 2022-12-06
EP4110469A1 (en) 2023-01-04
WO2021170879A1 (en) 2021-09-02
AR121440A1 (es) 2022-06-08
CN115427111A (zh) 2022-12-02
TW202140454A (zh) 2021-11-01
AU2021225364A1 (en) 2022-10-13
US20230219900A1 (en) 2023-07-13
MX2022010440A (es) 2022-10-18
IL295633A (en) 2022-10-01
CL2022002290A1 (es) 2023-02-03
JP2023519809A (ja) 2023-05-15
UY39098A (es) 2021-09-30
ECSP22066670A (es) 2022-12-30
CO2022012017A2 (es) 2022-11-18
PE20230347A1 (es) 2023-03-02

Similar Documents

Publication Publication Date Title
PE20050965A1 (es) Procedimiento para la preparacion de compuestos de aminocrotonilo
KR930017873A (ko) 피라졸 유도체, 그것을 제조하는 방법 및 그것을 함유하는 약학적 조성물
MX2010005997A (es) Derivados de aminobenzamida como agentes utiles para el control de parasitos de animales.
US11040963B2 (en) Piperazine derivatives for influenza virus inhibitions
PT2323972E (pt) Compostos de tetraciclina substituídos com c7-flúor
JP2016520063A5 (es)
PE20140966A1 (es) Quinazolincarboxamida azetidinas
HRP20090459T1 (hr) Aminofenil derivati kao novi inhibitori histonskih deacetilaza
PE20080364A1 (es) Acido bifenilcarboxilicos substituidos y sus derivados como moduladores de la actividad de la gamma-secretasa
HRP20090439T1 (hr) Supstituirani derivati propenil piperazina kao novi inhibitori histonske deacetilaze
BR112014032581A2 (pt) inibidores de bifluorodioxalano-amino-benzimidazol qui-nase para o tratamento de câncer, distúrbios do snc e inflamação autoimune
BR112012003464B8 (pt) compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica
IN2012DN02502A (es)
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
WO2010129057A3 (en) Tetracycline compounds
PE20141201A1 (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
NZ603108A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
CU20220047A7 (es) 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio monohidrato y su preparación
PE20142083A1 (es) Derivados de anilina, su preparacion y su aplicacion terapeutica
WO2018141854A1 (en) Piperazine derivatives for influenza virus inhibition
WO2010132670A3 (en) Pentacycline compounds
EA201270653A1 (ru) Антагонист dpи его применение
BRPI0510451A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas de ppar(delta) e/ou de ppar(alfa) e sua utilização
AU2004308578B2 (en) Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies
DK1179342T3 (da) Medicinske sammensætninger til öjeblikkelig frigivelse ved oral anvendelse